Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Regulatory Affairs Head Glavin Makes Retooling Of Field Force A Priority

Executive Summary

Management of FDA's field resources will be a top priority for Associate Commissioner for Regulatory Affairs Margaret Glavin as she undertakes a wide-ranging review of office practices

You may also be interested in...

FDA Rx Safety Website Will Include Drugs With Emerging Off-Label Issues

FDA's "Drug Watch" website will include safety information on drugs that have emerging safety signals for off-label uses

FDA Will Fund Research On “Critical Path” Of Drug Development

FDA's "Critical Path" initiative will redirect the agency's research funding towards identifying and alleviating some major barriers to drug development

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts